127P - Maximum treatment response and prophylactic cranial irradiation are important prognostic factors in limited disease small-cell lung cancer patients...

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Small-Cell Lung Cancer
Imaging, Diagnosis and Staging
Presenter Chukwuka Eze
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors C. Eze1, O. Roengvoraphoj2, S. Gerum3, C. Belka4, F. Manapov2
  • 1Radiation Oncology, Ludwig Maximilians University - Grosshadern, 81377 - München/DE
  • 2Radiation Oncology, Ludwig Maximilians University - Grosshadern, München/DE
  • 3Radiation Oncology, LMU Klinikum der Universität München, 81377 - München/DE
  • 4Radiation Oncology, LMU Klinikum der Universität München, 81375 - München/DE

Abstract

Background

The role of prophylactic cranial irradiation (PCI) in limited disease (LD) small-cell lung cancer (SCLC) has proven to significantly decrease the incidence of brain metastases (BMs) with only modest improvement of overall survival.

Methods

To evaluate the impact of PCI on survival we reviewed 179 LD SCLC patients treated with definitive chemoradiotherapy (CRT) in the concurrent or sequential setting. PCI was applied in the partial and complete responders exclusively provided contrast-enhanced cranial magnetic resonance imaging (cMRI) before and after primary treatment showed no signs of occult BMs. Correlation between PCI and time to progression (TTP) as well as overall survival (OS) was analysed. Kaplan–Meier analysis, uni- and multivariate Cox regression were used to describe survival within subgroups defined by treatment response and application of PCI.

Results

Concurrent and sequential chemoradiotherapy CRT was applied in 71 (40%) and 108 (60%) patients, respectively. In 58 (32%) patients metachronous BMs were detected. PCI was applied in 71 (39%) patients. 15 patients developed BMs after PCI. Median TTP and OS in responders treated with PCI were 812 and 801 compared to 355 (range: 284–456) (p 

Conclusions

In this LD SCLC patient cohort comprehensively staged with cMRI, achievement of maximum treatment response and application of PCI significantly affects time to progression and overall survival.

Clinical trial identification

Legal entity responsible for the study

Ethics Committee, University of Munich

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.